Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Decreased responsiveness to oxycodone: A case of a pharmacokinetic drug interaction?
View through CrossRef
Concurrent administration of oxycodone and phenytoin may cause, through induction of CYP3A4 enzymes, decreased analgesic effects of oxycodone. However, no descriptions of this interaction exist. A patient who was on oxycodone for chronic back pain was admitted to the hospital. Five days after initiating fosphenytoin, the patient experienced a dramatic escalation in his pain and lack of response to oxycodone breakthrough doses. Changing oxycodone to hydromorphone resulted in significantly improved analgesia. Concurrent use of fosphenytoin and oxycodone may increase the conversion of oxycodone to inactive metabolites, resulting in decreased analgesia. This may be avoided using hydromorphone, morphine, or oxymorphone.
Title: Decreased responsiveness to oxycodone: A case of a pharmacokinetic drug interaction?
Description:
Concurrent administration of oxycodone and phenytoin may cause, through induction of CYP3A4 enzymes, decreased analgesic effects of oxycodone.
However, no descriptions of this interaction exist.
A patient who was on oxycodone for chronic back pain was admitted to the hospital.
Five days after initiating fosphenytoin, the patient experienced a dramatic escalation in his pain and lack of response to oxycodone breakthrough doses.
Changing oxycodone to hydromorphone resulted in significantly improved analgesia.
Concurrent use of fosphenytoin and oxycodone may increase the conversion of oxycodone to inactive metabolites, resulting in decreased analgesia.
This may be avoided using hydromorphone, morphine, or oxymorphone.
Related Results
Monitoring oxycodone use in patients with chronic pain: Analysis of oxycodone and metabolite excretion in saliva and urine
Monitoring oxycodone use in patients with chronic pain: Analysis of oxycodone and metabolite excretion in saliva and urine
Objective: Saliva is purported to have a close correspondence to plasma concentrations due to a passive diffusion process from plasma to saliva. However, limited data are available...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Oxycodone 5 Miligram is More Effective Than Ketorolac 30 Miligram in Suppressing Cortisol Levels During General Anesthesia
Oxycodone 5 Miligram is More Effective Than Ketorolac 30 Miligram in Suppressing Cortisol Levels During General Anesthesia
Background: Preemptive analgesia is a developing clinical concept, which involves administering analgesics before pain stimulation occurs, to prevent the sensitization of the nervo...
Blockade of endocannabinoid system by oxytocin attenuates memory deficits in oxycodone‐treated rats
Blockade of endocannabinoid system by oxytocin attenuates memory deficits in oxycodone‐treated rats
AbstractOxycodone is a highly prescribed opioid and its abuse has been rampant. Accumulating evidence shows that the cannabinoid CB1 receptor (CB1R) plays a key role in mediating r...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Individualized Compared With Standard Postdischarge Oxycodone Prescribing After Cesarean Birth
Individualized Compared With Standard Postdischarge Oxycodone Prescribing After Cesarean Birth
OBJECTIVE:
To evaluate whether individualized postdischarge oxycodone prescribing guided by inpatient opioid use reduces the number of unused opioid tablets after cesar...
Oxycodone hydrochloride controlled‐release tablets (OxyContin®): post‐marketing surveillance (PMS) study for relieving moderate to severe non‐cancer pain
Oxycodone hydrochloride controlled‐release tablets (OxyContin®): post‐marketing surveillance (PMS) study for relieving moderate to severe non‐cancer pain
Objective: To evaluate the efficacy and safety of oxycodone hydrochloride controlled‐release (CR) tablets (Oxycontin®, Mundipharma International Limited, Cambridge, UK), 5 mg, 10 m...
Oxycodone target concentration dosing for acute pain in children
Oxycodone target concentration dosing for acute pain in children
AbstractBackgroundOxycodone pharmacokinetics have been described in premature neonates through to obese adults. Covariate influences have been accounted for using allometry (size) ...